$AMLX (Amylyx Pharmaceuticals, Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 85.2%)

Graded daily on value D-, growth B, profitability D, momentum A+, revisions A-. Sector-relative, identical for every user.

Most active credible voices on $AMLX

@zohmbastic (zohm) — 19 mentions · 11.4K followers
@semodough (dough) — 7 mentions · 44.6K followers
@marketrebels (Market Rebellion) — 6 mentions · 367.8K followers

Recent headlines featuring $AMLX

2026-08-18: Amylyx says avexitide cut severe hypoglycemia 55% in Phase 3, AMLX jumps 30.7% premarket

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $AMLX are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$AMLX — what investors on X are saying · SpikePanel

$AMLXAmylyx Pharmaceuticals, Inc. · Biotechnology · $4.1B

$31.25

post-1.7%

Event thread

Key events, in time order

12 items

2026-11-058-K filing
8-K: Item 2.02, Item 9.01
D1 -6.1% · since +11.9%
2026-11-05Earnings
Earnings report
D1 -6.1% · since +11.9%

10 earlier events

2026-09-098-K filing
8-K: Item 1.01
D1 -4.4% · +5d +0.7%
2026-08-218-K filing
8-K: Item 1.01, Item 9.01
D1 -2.5% · +5d -10.1%
2026-08-18 → 08-19CompanyBull
AMLX Reports Positive Phase III LUCIDITY Topline Data for Avexitide
Avexitide cuts hypoglycemic events by 55% in PBH; FDA filing planned by end-2026
D1 +63.8% · +5d +6.7%
3 waves of this story
- 2026-08-18 Company confirms topline readout today; after-hours shares rose on anticipation
- 2026-08-18 Avexitide met primary endpoint in PBH Phase 3 trial, supporting potential first treatment
- 2026-08-19 Avexitide cuts hypoglycemic events by 55% in PBH; FDA filing planned by end-2026
2026-08-198-K filing
8-K: Item 8.01, Item 9.01
D1 +9.9% · +5d -3.9%
2026-08-18 → 08-19Capital
AMLX Upsizes Offering to $500M, Priced at $35.49/Share
Company confirms upsized offering from $350M to $500M, 14.09M shares
D1 +63.8% · +5d +6.7%
2 waves of this story
- 2026-08-18 Company commenced underwritten offering, potentially funding avexitide commercialization and pipeline
- 2026-08-19 Company confirms upsized offering from $350M to $500M, 14.09M shares
2026-08-188-K filing
8-K: Item 7.01, Item 8.01, Item 9.01
D1 +63.8% · +5d +6.7%
2026-08-07Earnings
AMLX Q2 Results; LUCIDITY Phase 3 Top-line Data Expected Late Aug/Early Sept
Multiple sources confirm pivotal Phase 3 readout timing, driving stock expectations
D1 -5.7% · +5d -5.2%
2026-08-07Earnings
Baird Raises AMLX PT to $28, Keeps Outperform Ahead of LUCIDITY Readout
Baird updates model ahead of LUCIDITY Phase 3 readout, PT raised from $19 to $28
D1 -5.7% · +5d -5.2%
2 waves of this story
- 2026-08-07 Q2 call confirms avexitide Phase 3 in PBH completed visits; top-line imminent; Baird raises PT to $28
- 2026-08-07 Baird updates model ahead of LUCIDITY Phase 3 readout, PT raised from $19 to $28
2026-08-06Earnings
Earnings report
LUCIDITY III期试验最后一名患者已完成最后一次访视，顶线数据预计在8月底或9月初公布。
D1 +10.7% · +5d -7.1%
2026-08-068-K filing
8-K: Item 2.02, Item 9.01
D1 +10.7% · +5d -7.1%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

12 items

2026-11-058-K filing
8-K: Item 2.02, Item 9.01
D1 -6.1% · since +11.9%
2026-11-05Earnings
Earnings report
D1 -6.1% · since +11.9%
2026-09-098-K filing
8-K: Item 1.01
D1 -4.4% · +5d +0.7%
2026-08-218-K filing
8-K: Item 1.01, Item 9.01
D1 -2.5% · +5d -10.1%
2026-08-18 → 08-19CompanyBull
AMLX Reports Positive Phase III LUCIDITY Topline Data for Avexitide
Avexitide cuts hypoglycemic events by 55% in PBH; FDA filing planned by end-2026
D1 +63.8% · +5d +6.7%
3 waves of this story
- 2026-08-18 Company confirms topline readout today; after-hours shares rose on anticipation
- 2026-08-18 Avexitide met primary endpoint in PBH Phase 3 trial, supporting potential first treatment
- 2026-08-19 Avexitide cuts hypoglycemic events by 55% in PBH; FDA filing planned by end-2026

7 earlier events

2026-08-198-K filing
8-K: Item 8.01, Item 9.01
D1 +9.9% · +5d -3.9%
2026-08-18 → 08-19Capital
AMLX Upsizes Offering to $500M, Priced at $35.49/Share
Company confirms upsized offering from $350M to $500M, 14.09M shares
D1 +63.8% · +5d +6.7%
2 waves of this story
- 2026-08-18 Company commenced underwritten offering, potentially funding avexitide commercialization and pipeline
- 2026-08-19 Company confirms upsized offering from $350M to $500M, 14.09M shares
2026-08-188-K filing
8-K: Item 7.01, Item 8.01, Item 9.01
D1 +63.8% · +5d +6.7%
2026-08-07Earnings
AMLX Q2 Results; LUCIDITY Phase 3 Top-line Data Expected Late Aug/Early Sept
Multiple sources confirm pivotal Phase 3 readout timing, driving stock expectations
D1 -5.7% · +5d -5.2%
2026-08-07Earnings
Baird Raises AMLX PT to $28, Keeps Outperform Ahead of LUCIDITY Readout
Baird updates model ahead of LUCIDITY Phase 3 readout, PT raised from $19 to $28
D1 -5.7% · +5d -5.2%
2 waves of this story
- 2026-08-07 Q2 call confirms avexitide Phase 3 in PBH completed visits; top-line imminent; Baird raises PT to $28
- 2026-08-07 Baird updates model ahead of LUCIDITY Phase 3 readout, PT raised from $19 to $28
2026-08-06Earnings
Earnings report
LUCIDITY III期试验最后一名患者已完成最后一次访视，顶线数据预计在8月底或9月初公布。
D1 +10.7% · +5d -7.1%
2026-08-068-K filing
8-K: Item 2.02, Item 9.01
D1 +10.7% · +5d -7.1%

$AMLX (Amylyx Pharmaceuticals, Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 85.2%)

Most active credible voices on $AMLX

Recent headlines featuring $AMLX

$AMLX (Amylyx Pharmaceuticals, Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 85.2%)

Most active credible voices on $AMLX

Recent headlines featuring $AMLX

8-K: Item 2.02, Item 9.01

Earnings report

8-K: Item 1.01

8-K: Item 1.01, Item 9.01

AMLX Reports Positive Phase III LUCIDITY Topline Data for Avexitide

8-K: Item 8.01, Item 9.01

AMLX Upsizes Offering to $500M, Priced at $35.49/Share

8-K: Item 7.01, Item 8.01, Item 9.01

AMLX Q2 Results; LUCIDITY Phase 3 Top-line Data Expected Late Aug/Early Sept

Baird Raises AMLX PT to $28, Keeps Outperform Ahead of LUCIDITY Readout

Earnings report

8-K: Item 2.02, Item 9.01

Bull vs bear

Discussion

8-K: Item 2.02, Item 9.01

Earnings report

8-K: Item 1.01

8-K: Item 1.01, Item 9.01

AMLX Reports Positive Phase III LUCIDITY Topline Data for Avexitide

8-K: Item 8.01, Item 9.01

AMLX Upsizes Offering to $500M, Priced at $35.49/Share

8-K: Item 7.01, Item 8.01, Item 9.01

AMLX Q2 Results; LUCIDITY Phase 3 Top-line Data Expected Late Aug/Early Sept

Baird Raises AMLX PT to $28, Keeps Outperform Ahead of LUCIDITY Readout

Earnings report

8-K: Item 2.02, Item 9.01